scholarly journals Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes

2014 ◽  
Author(s):  
Ishii
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Low Dose ◽  
Japanese Patients

scholarly journals Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 8 (1) ◽  
pp. 45 ◽  
Author(s):  
Tamara Y. Milder ◽  
Sophie L. Stocker ◽  
Christina Abdel Shaheed ◽  
Lucy McGrath-Cadell ◽  
Dorit Samocha-Bonet ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Low Dose ◽  
Meta Analysis ◽  
Sglt2 Inhibitor ◽  
Cochrane Library ◽  
High Dose ◽  
Dose Combination ◽  
Inhibitor Combination

Background: Guidelines differ with regard to indications for initial combination pharmacotherapy for type 2 diabetes. Aims: To compare the efficacy and safety of (i) sodium-glucose cotransporter 2 (SGLT2) inhibitor combination therapy in treatment-naïve type 2 diabetes adults; (ii) initial high and low dose SGLT2 inhibitor combination therapy. Methods: PubMed, Embase and Cochrane Library were searched for randomised controlled trials (RCTs) of initial SGLT2 combination therapy. Mean difference (MD) for changes from baseline (HbA1c, weight, blood pressure) after 24–26 weeks of treatment and relative risks (RR, safety) were calculated using a random-effects model. Risk of bias and quality of evidence was assessed. Results: In 4 RCTs (n = 3749) there was moderate quality evidence that SGLT2 inhibitor/metformin combination therapy resulted in a greater reduction in HbA1c (MD (95% CI); −0.55% (−0.67, −0.43)) and weight (−2.00 kg (−2.34, −1.66)) compared with metformin monotherapy, and a greater reduction in HbA1c (−0.59% (−0.72, −0.46)) and weight (−0.57 kg (−0.89, −0.25)) compared with SGLT2 inhibitor monotherapy. The high dose SGLT2 inhibitor/metformin combination resulted in a similar HbA1c but greater weight reduction; −0.47 kg (−0.88, −0.06) than the low dose combination therapy. The RR of genital infection with combination therapy was 2.22 (95% CI 1.33, 3.72) and 0.69 (95% CI 0.50, 0.96) compared with metformin and SGLT2 inhibitor monotherapy, respectively. The RR of diarrhoea was 2.23 (95% CI 1.46, 3.40) with combination therapy compared with SGLT2 inhibitor monotherapy. Conclusions: Initial SGLT2 inhibitor/metformin combination therapy has glycaemic and weight benefits compared with either agent alone and appears relatively safe. High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy.

Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin

2017 ◽  
Vol 18 (18) ◽  
pp. 1921-1928 ◽  
Author(s):  
Luka Suzuki ◽  
Akio Kanazawa ◽  
Hirotsugu Uzawa ◽  
Yusuke Osonoi ◽  
Atushi Masuyama ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Low Dose ◽  
Japanese Patients ◽  
Safety And Efficacy

scholarly journals Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

2016 ◽  
Vol 7 (4) ◽  
pp. 565-573 ◽  
Author(s):  
Yutaka Seino ◽  
Shizuka Kaneko ◽  
Shuichi Fukuda ◽  
Takeshi Osonoi ◽  
Toshihiko Shiraiwa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Japanese Patients ◽  
Double Blind ◽  
Parallel Group ◽  
Parallel Group Trial ◽  
Group Trial

scholarly journals Effects of Pretreatment with Low-dose Metformin on Metabolic Parameters and Weight Gain by Pioglitazone in Japanese Patients with Type 2 Diabetes

2008 ◽  
Vol 47 (13) ◽  
pp. 1181-1188 ◽  
Author(s):  
Toshihide Kawai ◽  
Osamu Funae ◽  
Akira Shimada ◽  
Mitsuhisa Tabata ◽  
Takumi Hirata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Gain ◽  
Low Dose ◽  
Japanese Patients ◽  
Metabolic Parameters
Sign in / Sign up

Export Citation Format

Share Document